GSK may pay high price in US to settle China graft allegations, say lawyers

New York-listed GlaxoSmithKline may pay a record amount in the United States to settle China-related corruption allegations, if it is charged under the Foreign Corrupt Practices Act (FCPA), given the extent of its alleged malpractices.

via Business feed http://www.scmp.com/business/companies/article/1295403/gsk-may-pay-high-price-us-settle-china-graft-allegations-say